Psoriatic Disease News

The single-injection 2 mL prefilled syringe and autoinjector for Bimzelx 320 mg is now available, UCB announced in a press release.

The VISIBLE trial demonstrated that intentional efforts to recruit and retain patients with skin of color result in a speedy enrollment process and diverse patient pool, according to a study.

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & Therapy.

The FDA has approved the Stelara biosimilar Steqeyma for the treatment of adults and children with plaque psoriasis and psoriatic arthritis and adults with Crohn’s disease and ulcerative colitis, Celltrion announced in a press release.

Johnson & Johnson has submitted two supplemental biologics license applications to the FDA for Tremfya for the treatment of plaque psoriasis and juvenile psoriatic arthritis in children, the company announced in a press release.

The FDA has approved the Stelara biosimilar Yesintek for indications matching the reference product, with a commercial launch date expected for early 2025, according to a press release from Biocon Biologics.

An in-depth interview about the effects of the CMS’s 2025 physician fee schedule on patient access topped Healio Dermatology’s most-read articles of November, with FDA news also garnering attention.

WASHINGTON — Patients with inflammatory arthritis who receive rituximab, interleukin-6 inhibition or Janus kinase inhibitors demonstrate higher severe infection risks vs. TNF inhibitors, according to data presented at ACR Convergence 2024.

WASHINGTON — Dactylitis, psoriasis and other non-musculoskeletal manifestations of psoriatic arthritis can be accurately monitored through patient self-reporting, according to data presented at ACR Convergence 2024.